A drug discovery platform to identify compounds that inhibit EGFR triple mutants-Reference-Cited by-同舟云学术

A drug discovery platform to identify compounds that inhibit EGFR triple mutants

Published:2020-02-24 Issue:5 Volume:16 Page:577-586
ISSN:1552-4450
Container-title:Nature Chemical Biology
language:en
Short-container-title:Nat Chem Biol

Author:

Saraon Punit,Snider Jamie,Kalaidzidis Yannis^ORCID,Wybenga-Groot Leanne E.,Weiss Konstantin,Rai Ankit^ORCID,Radulovich Nikolina,Drecun Luka,Vučković Nika,Vučetić Adriana,Wong Victoria,Thériault Brigitte,Pham Nhu-An,Park Jin H.,Datti Alessandro,Wang Jenny,Pathmanathan Shivanthy,Aboualizadeh Farzaneh,Lyakisheva Anna,Yao Zhong,Wang Yuhui,Joseph Babu,Aman Ahmed,Moran Michael F.,Prakesch Michael,Poda Gennady,Marcellus Richard,Uehling David,Samaržija Miroslav,Jakopović Marko,Tsao Ming-Sound,Shepherd Frances A.,Sacher Adrian,Leighl Natasha,Akhmanova Anna^ORCID,Al-awar Rima,Zerial Marino^ORCID,Stagljar Igor^ORCID

Funder

Canadian Cancer Society Research Institute

Cancer Research Society

Consortium Québécois sur la Découverte du Médicament (CQDM) (Explore) and OCE (#23929) Genome Canada via Ontario Genomics

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology

Link

http://www.nature.com/articles/s41589-020-0484-2.pdf

Reference43 articles.

1. Lemmon, M. A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 141, 1117–1134 (2010).